Skip to main content
SpringerLink
Log in
Book cover

Cell Biology of the Ovary pp 135–151Cite as

Clinical Management of Epithelial Ovarian Cancer

  • Chapter
  • First Online:

  • 640 Accesses

Abstract

Ovarian cancer has high morbidity and mortality worldwide, and its mortality is the highest among female genital cancers. Improvement in clinical outcome is an urgent issue for ovarian cancer, and clinical management including treatment has been repeatedly studied. Tumor markers such as CA125, CA19–9, and HE4 and image diagnosis using MRI, CT, PET, etc. are indispensable diagnostic aid tools. In the initial treatment, primary debulking surgery (PDS) is basically effective, but fertility preservation can be considered depending on the case. For advanced cancers, interval debulking surgery (IDS) is considered after several cycles of neoadjuvant chemotherapy (NAC). Although the combination of paclitaxel and carboplatin (TC) regimen was originally established as the standard chemotherapy for ovarian cancer regardless of tissue type, new treatments in clinical trials, including molecular-targeted therapeutic agents, are being investigated. The main treatment for recurrent cancer is chemotherapy, and sensitivity to chemotherapy based on the disease-free interval has been considered in the choice of treatment. Furthermore, in recent years, risk-reducing bilateral salpingo-oophorectomy has been undertaken to prevent the onset of hereditary breast and ovarian cancer. It is also being studied how to manage the follow-up after treatment and hormone replacement.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40.

    Article  PubMed  Google Scholar 

  2. Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Philadelphia, PA). 2011;4:365–74.

    Article  Google Scholar 

  3. Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012;22:S24–6.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Drescher CW, Shah C, Thorpe J, et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:387–92.

    Article  Google Scholar 

  5. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.

    Article  CAS  PubMed  Google Scholar 

  7. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity. N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Gubbels JA, Felder M, Horibata S, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival – a review of the epidemiological literature. J Ovarian Res. 2009;2:13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Morales-Vasquez F, Pedernera E, Reynaga-Obregon J, et al. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res. 2016;9:41.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hogdall EV, Christensen L, Kjaer SK, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol. 2007;104:508–15.

    Article  CAS  PubMed  Google Scholar 

  12. Riedinger JM, Wafflart J, Ricolleau G, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17:1234–8.

    Article  CAS  PubMed  Google Scholar 

  13. Lee CK, Friedlander M, Brown C, et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst. 2011;103:1338–42.

    Article  CAS  PubMed  Google Scholar 

  14. Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecol Oncol. 2009;115:81–5.

    Article  PubMed  PubMed Central  Google Scholar 

  15. van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol. 2010;119:265–9.

    Article  PubMed  CAS  Google Scholar 

  16. Geurts SM, de Vegt F, van Altena AM, et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011;21:837–45.

    Article  PubMed  Google Scholar 

  17. Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21–31.

    Article  CAS  PubMed  Google Scholar 

  18. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (London). 2010;376:1155–63.

    Article  Google Scholar 

  19. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957–71.

    Article  CAS  PubMed  Google Scholar 

  20. Cho HY, Kyung MS. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study. Med Sci Monitor. 2014;20:1334–9.

    Article  CAS  Google Scholar 

  21. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J. 2002;368:233–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.

    Article  CAS  PubMed  Google Scholar 

  23. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modern Pathol. 2006;19:847–53.

    Article  CAS  Google Scholar 

  24. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273–81.

    Article  CAS  PubMed  Google Scholar 

  25. Jia MM, Deng J, Cheng XL, et al. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. Oncotarget. 2017;8:9660–71.

    PubMed  Google Scholar 

  26. Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA. US characterization of ovarian masses: a meta-analysis. Radiology. 2000;217:803–11.

    Article  CAS  PubMed  Google Scholar 

  27. Bazot M, Darai E, Nassar-Slaba J, Lafont C, Thomassin-Naggara I. Value of magnetic resonance imaging for the diagnosis of ovarian tumors: a review. J Comput Assist Tomogr. 2008;32:712–23.

    Article  PubMed  Google Scholar 

  28. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis. Radiology. 2000;214:39–46.

    Article  CAS  PubMed  Google Scholar 

  29. Bazot M, Nassar-Slaba J, Thomassin-Naggara I, Cortez A, Uzan S, Darai E. MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors; correlation with final histology. Eur Radiol. 2006;16:2687–99.

    Article  PubMed  Google Scholar 

  30. Moyle P, Addley HC, Sala E. Radiological staging of ovarian carcinoma. Semin Ultrasound CT MR. 2010;31:388–98.

    Article  PubMed  Google Scholar 

  31. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol. 2010;194:311–21.

    Article  PubMed  Google Scholar 

  32. Thomassin-Naggara I, Balvay D, Aubert E, et al. Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. Eur Radiol. 2012;22:738–45.

    Article  PubMed  Google Scholar 

  33. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188:1622–35.

    Article  PubMed  Google Scholar 

  34. Thomassin-Naggara I, Darai E, Cuenod CA, et al. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol. 2009;19:1544–52.

    Article  PubMed  Google Scholar 

  35. Takeuchi M, Matsuzaki K, Nishitani H. Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr. 2010;34:173–6.

    Article  PubMed  Google Scholar 

  36. Komiyama S, Katabuchi H, Mikami M, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer. Int J Clin Oncol. 2016;21:435–46.

    Article  PubMed  Google Scholar 

  37. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:1248–59.

    Article  Google Scholar 

  38. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560–6.

    Article  PubMed  Google Scholar 

  39. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:8802–11.

    Article  Google Scholar 

  40. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.

    Article  PubMed  Google Scholar 

  41. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115:1234–44.

    Article  PubMed  CAS  Google Scholar 

  42. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559–64.

    Article  CAS  PubMed  Google Scholar 

  43. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083–90.

    Article  PubMed  Google Scholar 

  44. Bristow RE, Peiretti M, Zanagnolo V, Salani R, Giuntoli RL II, Maggioni A. Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcome. Gynecol Oncol. 2008;109:364–9.

    Article  PubMed  Google Scholar 

  45. Juretzka MM, Barakat RR. Pelvic cytoreduction with rectosigmoid resection. Gynecol Oncol. 2007;104:40–4.

    Article  PubMed  Google Scholar 

  46. Ayhan A, Gultekin M, Taskiran C, et al. Routine appendectomy in epithelial ovarian carcinoma: is it necessary? Obstet Gynecol. 2005;105:719–24.

    Article  PubMed  Google Scholar 

  47. Dietrich CS III, Desimone CP, Modesitt SC, et al. Primary appendiceal cancer: gynecologic manifestations and treatment options. Gynecol Oncol. 2007;104:602–6.

    Article  PubMed  Google Scholar 

  48. Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W. Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol. 2008;109:303–7.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol. 2010;116:497–501.

    Article  PubMed  Google Scholar 

  50. Eisenkop SM, Spirtos NM, Lin WC. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol. 2006;100:344–8.

    Article  PubMed  Google Scholar 

  51. Marpeau O, Schilder J, Zafrani Y, et al. Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol. 2008;15:478–83.

    Article  PubMed  Google Scholar 

  52. Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol. 2006;103:878–82.

    Article  PubMed  Google Scholar 

  53. Satoh T, Tsuda H, Kanato K, et al. A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203). Jpn J Clin Oncol. 2015;45:595–9.

    Article  PubMed  Google Scholar 

  54. Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1727–32.

    Article  Google Scholar 

  55. Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol. 2011;123:187–91.

    Article  CAS  PubMed  Google Scholar 

  56. Gerestein CG, Damhuis RA, de Vries M, Reedijk A, Burger CW, Kooi GS. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer (Oxford, England: 1990). 2009;45:2799–803.

    Article  CAS  Google Scholar 

  57. Lim MC, Kang S, Song YJ, Park SH, Park SY. Feasibility and safety of extensive upper abdominal surgery in elderly patients with advanced epithelial ovarian cancer. J Korean Med Sci. 2010;25:1034–40.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Onda T, Kobayashi H, Nakanishi T, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol. 2009;113:57–62.

    Article  PubMed  Google Scholar 

  61. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet (London). 2015;386:249–57.

    Article  Google Scholar 

  62. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  CAS  PubMed  Google Scholar 

  63. Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer (Oxford, England: 1990). 2016;64:22–31.

    Article  Google Scholar 

  64. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92:2585–91.

    Article  CAS  PubMed  Google Scholar 

  65. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res. 2006;32:99–106.

    Article  CAS  PubMed  Google Scholar 

  66. Hegazy MA, Hegazi RA, Elshafei MA, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol. 2005;3:57.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 2006;27:25–8.

    CAS  PubMed  Google Scholar 

  68. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol. 2003;88:9–16.

    Article  CAS  PubMed  Google Scholar 

  69. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3194–200.

    Article  CAS  Google Scholar 

  70. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.

    Article  PubMed  CAS  Google Scholar 

  71. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1419–25.

    Article  CAS  Google Scholar 

  72. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet (London). 2009;374:1331–8.

    Article  CAS  Google Scholar 

  73. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19:1001–7.

    Article  CAS  Google Scholar 

  74. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  CAS  PubMed  Google Scholar 

  75. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;2016:Cd005340.

    Google Scholar 

  76. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005;97:10–5.

    Article  CAS  PubMed  Google Scholar 

  77. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003;90:637–43.

    Article  CAS  PubMed  Google Scholar 

  78. Fujiwara K, Nagao S, Kigawa J, et al. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer. 2009;19:834–7.

    Article  PubMed  Google Scholar 

  79. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682–91.

    Article  CAS  PubMed  Google Scholar 

  80. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3628–35.

    Article  CAS  Google Scholar 

  81. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstetr. 2006;95:S161–92.

    Article  Google Scholar 

  82. Ho CM, Huang YJ, Chen TC, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004;94:197–203.

    Article  CAS  PubMed  Google Scholar 

  83. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Utsunomiya H, Akahira J, Tanno S, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer. 2006;16:52–6.

    Article  CAS  PubMed  Google Scholar 

  85. Takano M, Kikuchi Y, Yaegashi N, et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep. 2006;16:1301–6.

    CAS  PubMed  Google Scholar 

  86. Takano M, Sugiyama T, Yaegashi N, et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol. 2007;12:256–60.

    Article  CAS  PubMed  Google Scholar 

  87. Sugiyama T, Yakushiji M, Kamura T, et al. Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology. 2002;63:16–22.

    Article  CAS  PubMed  Google Scholar 

  88. Sugiyama T, Okamoto A, Enomoto T, et al. Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2881–7.

    Article  CAS  Google Scholar 

  89. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985–93.

    Article  PubMed  Google Scholar 

  90. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331–4.

    Article  PubMed  Google Scholar 

  91. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1040–4.

    Article  CAS  Google Scholar 

  92. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.

    Article  CAS  PubMed  Google Scholar 

  93. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.

    Article  CAS  PubMed  Google Scholar 

  94. Eisenhauer EL, Tew WP, Levine DA, et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106:381–7.

    Article  CAS  PubMed  Google Scholar 

  95. Hilpert F, du Bois A, Greimel ER, et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or =70 years with advanced ovarian cancer—a study by the AGO OVAR Germany. Ann Oncol. 2007;18:282–7.

    Article  CAS  PubMed  Google Scholar 

  96. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3–11.

    Article  CAS  PubMed  Google Scholar 

  97. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol. 2007;64:129–38.

    Article  PubMed  Google Scholar 

  98. Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3120–5.

    Article  CAS  Google Scholar 

  99. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (London). 2003;361:2099–106.

    Article  CAS  Google Scholar 

  100. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15:36–41.

    Article  PubMed  Google Scholar 

  101. Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 2002;3:537–45.

    Article  CAS  PubMed  Google Scholar 

  102. Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol. 2001;83:128–34.

    Article  CAS  PubMed  Google Scholar 

  103. Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90:2112–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3176–82.

    Article  CAS  Google Scholar 

  105. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16:749–55.

    Article  CAS  PubMed  Google Scholar 

  106. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:2039–45.

    Article  CAS  Google Scholar 

  107. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1302–8.

    Article  CAS  Google Scholar 

  108. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.

    Article  PubMed  Google Scholar 

  109. Tinger A, Waldron T, Peluso N, et al. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys. 2001;51:1256–63.

    Article  CAS  PubMed  Google Scholar 

  110. E C QM, Gallant V, Samant R. Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. Gynecol Oncol. 2006;102:204–9.

    Article  PubMed  Google Scholar 

  111. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24–32.

    Article  PubMed  Google Scholar 

  112. Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol. 1993;82:143–7.

    CAS  PubMed  Google Scholar 

  113. Gadducci A, Sartori E, Maggino T, et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol. 1998;68:150–5.

    Article  CAS  PubMed  Google Scholar 

  114. Dembo AJ. Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of matured data. J Clin Oncol Off J Am Soc Clin Oncol. 1986;4:1573–6.

    Article  CAS  Google Scholar 

  115. Aebi S, Castiglione M. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:ii14–6.

    Article  PubMed  Google Scholar 

  116. Harmandayan GZ, Gao F, Mutch DG, Virgo KS, Gibb RK, Johnson FE. Ovarian cancer patient surveillance after curative-intent initial treatment. Gynecol Oncol. 2011;120:205–8.

    Article  PubMed  Google Scholar 

  117. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19:367–74.

    Article  PubMed  Google Scholar 

  118. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117:336–40.

    Article  PubMed  Google Scholar 

  119. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7:821–8.

    Article  PubMed  Google Scholar 

  120. Mascarenhas C, Lambe M, Bellocco R, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer. 2006;119:2907–15.

    Article  CAS  PubMed  Google Scholar 

  121. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer. 1999;86:1013–8.

    Article  CAS  PubMed  Google Scholar 

  122. Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ (Clin Res ed). 1991;302:259–62.

    Article  CAS  Google Scholar 

  123. Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause (New York, NY). 2001;8:70–5.

    Article  CAS  Google Scholar 

  124. Li L, Pan Z, Gao K, et al. Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncol Lett. 2012;3:244–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

    Yusuke Kobayashi, Hiroyuki Nomura, Fumio Kataoka, Eiichiro Tominaga, Kouji Banno & Daisuke Aoki

Authors
  1. Yusuke Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumio Kataoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eiichiro Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kouji Banno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daisuke Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yusuke Kobayashi .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

    Hidetaka Katabuchi

  2. Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

    Takashi Ohba

  3. Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

    Takeshi Motohara

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kobayashi, Y., Nomura, H., Kataoka, F., Tominaga, E., Banno, K., Aoki, D. (2018). Clinical Management of Epithelial Ovarian Cancer. In: Katabuchi, H., Ohba, T., Motohara, T. (eds) Cell Biology of the Ovary. Springer, Singapore. https://doi.org/10.1007/978-981-10-7941-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7941-2_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7940-5

  • Online ISBN: 978-981-10-7941-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation